Maheshkumar Vyas, MD
Allergy & Immunology · Anaheim, CANPI 1942279633
Payments from drug & device makers
Across 71 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$447
- Sanofi$293
- Regeneron Healthcare Solutions, Inc.$257
- Novartis$133
- Biocryst US Sales Co., LLC$131
- Bioventus LLC$67
- plus $314 from 13 others
What the payments were for
- Food & beverage$1,643100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $447 |
| Sanofi | 19 | $293 |
| Regeneron Healthcare Solutions, Inc. | 9 | $257 |
| Novartis | 5 | $133 |
| Biocryst US Sales Co., LLC | 4 | $131 |
| Bioventus LLC | 3 | $67 |
| Genentech USA, Inc. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Boston Scientific | 1 | $35 |
| Siemens Medical Solutions USA, Inc. | 1 | $32 |
| Fidia Pharma USA Inc. | 1 | $32 |
| Pfizer | 1 | $23 |
| Vertex | 1 | $20 |
| Baudax Bio Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Kaleo, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Johnson & Johnson | 1 | $7 |
How this compares
$1,643 in reported general payments places this provider in the 40th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 12 | $29,538 |
| Montelukast Sodium | 41 | $487 |
| Fluticasone Propionate | 19 | $465 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Anaheim
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
- James WolfeSan Jose$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.